Mounjaro vs. Zepbound: same tirzepatide, different FDA-approved uses

01

One active ingredient does not create one regulatory identity

Both brands list tirzepatide as the active ingredient and describe it as an agonist at glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors. That shared pharmacologic ingredient explains why consumers encounter the names together, but FDA approves defined drug products and labeling rather than ingredients in the abstract.

Mounjaro is associated with NDA 215866 and Zepbound with NDA 217806. Each application has its own approval history, labeling supplements, presentations, National Drug Codes, and approved uses. The label on the dispensed package—not a generic reference to tirzepatide—controls which branded product a patient received.

This is why a provider statement such as 'tirzepatide is FDA-approved' needs more detail. A complete claim identifies the brand or application, dosage form, route, patient population, and intended use. It also says when the label was checked because indications and warnings can change.

02

What Mounjaro's current label covers

The current DailyMed label identifies Mounjaro as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients age 10 years and older with type 2 diabetes mellitus. FDA originally approved Mounjaro in May 2022 for adults, and the label has since been updated, including for the pediatric population.

That label does not make the Mounjaro brand FDA-approved for every purpose associated with tirzepatide. A clinician may make an individualized prescribing decision under applicable law, but an off-label use should be described as off-label rather than converted into a new FDA-approved indication.

The brand also exists in specified presentations and package configurations. Consumers researching a shipment should match the brand name, active ingredient, strength, dosage form, manufacturer or labeler, NDC, lot, and pharmacy information. A familiar carton color or ingredient name is not enough to establish product identity.

03

What Zepbound's current label covers

Zepbound's current label includes long-term reduction and maintenance of excess body weight in specified adults with obesity or overweight and at least one weight-related comorbid condition. It also includes treatment of moderate-to-severe obstructive sleep apnea in adults with obesity. Both labeled uses include reduced-calorie diet and increased physical activity.

FDA first approved Zepbound for chronic weight management in November 2023. In December 2024, FDA approved the obstructive-sleep-apnea indication for adults with obesity. The approval was product- and population-specific; it did not authorize tirzepatide for every type of sleep apnea or every person with obesity.

The current Zepbound record includes single-dose and multidose presentations. Coverage programs may name only some presentations, as the 2026 Medicare GLP-1 Bridge does. Approval, availability, prescription terms, and coverage are separate questions that should be checked against separate records.

04

What is shared and what remains different

Because the active ingredient is shared, the labels contain overlapping safety concepts, including a boxed warning concerning thyroid C-cell tumors observed in rats and contraindications tied to medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. A shared warning does not erase the differences in approved use or make the brands freely substitutable.

The indicated populations differ. The current Mounjaro indication includes qualifying pediatric patients with type 2 diabetes; the current Zepbound indications are written for adults. Product presentations and instructions can also differ as labels are revised. Consumers should not construct a regimen by merging selected language from both labels.

Coverage may follow the diagnosis and labeled or medically accepted indication. For example, a plan or demonstration may process one brand for one purpose but not another. An advertising statement that the ingredient is covered should be tested against the patient's plan, the prescribed brand, the exact use, and current prior-authorization criteria.

05

How to verify a clinic's tirzepatide claim

Ask the clinic to state whether it is discussing Mounjaro, Zepbound, or a compounded tirzepatide preparation. Obtain the product name before paying, then compare the current DailyMed and Drugs@FDA records for the exact application. Record the proposed use separately from the approved indication.

If the clinic offers an approved brand, identify the dispensing pharmacy and verify the pharmacy license. When the package arrives, compare the prescription label, manufacturer packaging, dosage form, NDC, lot information, and patient instructions with what was ordered. Contact the prescriber or pharmacist when material details conflict.

If the clinic proposes compounding, ask why a compounded product is being considered for the identified patient, which licensed pharmacy will prepare it, and how the formulation differs from approved products. FDA states that compounded drugs do not undergo premarket review for safety, effectiveness, or quality and should not be called generic Mounjaro or generic Zepbound.

• →Exact brand or compounded status
• →NDA and current label
• →Proposed versus approved use
• →Dosage form and presentation
• →Named prescriber and pharmacy
• →Current coverage pathway
• →Follow-up and adverse-effect support

06

Comparison limits and treatment decisions

A regulatory comparison is not a recommendation to use either product and does not determine which, if any, is appropriate. The labels contain contraindications, warnings, interactions, adverse reactions, and population-specific information that cannot be reduced to an ingredient match.

Avoid provider claims that call the products identical, describe off-label use as approved, guarantee outcomes, or use an approval for one brand to validate a compounded vial. Also question claims that cite a trial, insurance policy, or FDA action without identifying which application, population, outcome, and date it concerns.

Discuss treatment choices with an appropriately licensed clinician who can review the current label, medical history, other medications, risks, alternatives, and monitoring. Seek urgent medical care for a suspected emergency. This directory does not recommend a product, dose, titration plan, or substitution.